Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angus G Jones

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
Nature Medicine|December 8, 2022
Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster studyBeverley M Shields, John M Dennis, Catherine D Angwin, et al.
Annals of Clinical Biochemistry|May 10, 2012
The impact of gender on urine C-peptide creatinine ratio interpretationNicholas J Thomas, Beverley M Shields, Rachel E J Besser, et al.
The Journal of Clinical Endocrinology and Metabolism|September 8, 2022
Islet Autoantibody Level Distribution in Type 1 Diabetes and Their Association With Genetic and Clinical CharacteristicsSian Louise Grace, Jack Bowden, Helen C Walkey, et al.
Diabetes, Obesity & Metabolism|November 19, 2016
Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetesDavid Preiss, Adem Dawed, Paul Welsh, et al.
Diabetes Care|October 21, 2021
Adult-Onset Type 1 Diabetes: Current Understanding and ChallengesR David Leslie, Carmella Evans-Molina, Jacquelyn Freund-Brown, et al.
Diabetologia|June 5, 2024
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approachLaura M Güdemann, Katie G Young, Nicholas J M Thomas, et al.
Diabetes Care|October 14, 2025
Updating a Clinical Prediction Model for Identifying Monogenic Diabetes to Include Both Clinical Features and BiomarkersJulieanne Knupp, Pedro Cardoso, Katherine G Young, et al.
The Lancet. Primary Care|May 11, 2026
Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care dataThijs T Jansz, Andrew P McGovern, Katherine G Young, et al.
Lancet (London, England)|February 28, 2025
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation studyJohn M Dennis, Katherine G Young, Pedro Cardoso, et al.
Diabetes Care|August 4, 2018
Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial DataJohn M Dennis, William E Henley, Michael N Weedon, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
Nature Medicine|December 8, 2022
Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster studyBeverley M Shields, John M Dennis, Catherine D Angwin, et al.
Annals of Clinical Biochemistry|May 10, 2012
The impact of gender on urine C-peptide creatinine ratio interpretationNicholas J Thomas, Beverley M Shields, Rachel E J Besser, et al.
The Journal of Clinical Endocrinology and Metabolism|September 8, 2022
Islet Autoantibody Level Distribution in Type 1 Diabetes and Their Association With Genetic and Clinical CharacteristicsSian Louise Grace, Jack Bowden, Helen C Walkey, et al.
Diabetes, Obesity & Metabolism|November 19, 2016
Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetesDavid Preiss, Adem Dawed, Paul Welsh, et al.
Diabetes Care|October 21, 2021
Adult-Onset Type 1 Diabetes: Current Understanding and ChallengesR David Leslie, Carmella Evans-Molina, Jacquelyn Freund-Brown, et al.
Diabetologia|June 5, 2024
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approachLaura M Güdemann, Katie G Young, Nicholas J M Thomas, et al.
Diabetes Care|October 14, 2025
Updating a Clinical Prediction Model for Identifying Monogenic Diabetes to Include Both Clinical Features and BiomarkersJulieanne Knupp, Pedro Cardoso, Katherine G Young, et al.
The Lancet. Primary Care|May 11, 2026
Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care dataThijs T Jansz, Andrew P McGovern, Katherine G Young, et al.
Lancet (London, England)|February 28, 2025
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation studyJohn M Dennis, Katherine G Young, Pedro Cardoso, et al.
Diabetes Care|August 4, 2018
Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial DataJohn M Dennis, William E Henley, Michael N Weedon, et al.
Pageof 10